Impact of obesity on the prognostic value of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction

Heart

Volumn 97, Issue 7, 2011, Pages 551-556

  Lorgis, Luc ^a   Cottin, Y ^a   Danchin, N ^b   Mock, L ^c   Sicard, P ^d   Buffet, P ^a   L'Huillier, I ^a   Richard, C ^a   Beer, J C ^a   Touzery, C ^a   Gambert, P ^a   Zeller, M ^d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Clinique de Fontaine   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FRANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; OBESITY; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79952534921     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.213041     Document Type: Article

References (29)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8. (Pubitemid 28366422)
2. Martinez-Rumayor A, Richards AM, Burnett JC, et al. Biology of the natriuretic peptides. Am J Cardiol 2008;101:3-8.
3. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
4. Omland T, Persson A, Ng L, et al. N-terminal pro B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-18. (Pubitemid 35424741)
5. Lorgis L, Zeller M, Dentan G, et al; RICO Survey Working Group. Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. BMJ 2009;338:b1605.
6. Luchner A, Burnett JC Jr, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
7. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5. (Pubitemid 38561338)
8. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600. (Pubitemid 38198866)
9. Taylor JA, Christenson RH, Rao K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006;152:1071-6. (Pubitemid 44854793)
10. Hong SN, Ahn Y, Yoon NS, et al. N-terminal pro-B-type natriuretic peptide level is depressed in patients with significant coronary artery disease who have high body mass index. Int Heart J 2008;49:403-12.
11. Zeller M, Steg PG, Ravisy J, et al; RICO Survey Working Group. Relation between body mass index, waist circumference, and death after acute myocardial infarction. Circulation 2008;118:482-90.
12. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report on a WHO Consultation. Geneva, Switzerland: World Health Organization, 2000.
13. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
14. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
15. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211-19.
16. Buettner HJ, Mueller C, Gick M, et al. The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J 2007;28:1694-701. (Pubitemid 47227103)
17. Nigam A, Wright RS, Allison TG, et al. Excess weight at time of presentation of myocardial infarction is associated with lower initial mortality risks but higher longterm risks including recurrent re-infarction and cardiac death. Int J Cardiol 2006;110:153-9. (Pubitemid 43767099)
18. Frankenstein L, Remppis A, Nelles M, et al. Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 2008;29:2634-40.
19. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006;47:85-90. (Pubitemid 43005169)
20. Noveanu M, Breidthardt T, Cayir S, et al. B-type natriuretic peptide-guided management and outcome in patients with obesity and dyspnea-results from the BASEL study. Am Heart J 2009;158:488-95.
21. Sarzani R, Dessì-Fulgheri P, Paci VM, et al. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19:581-5. (Pubitemid 26408098)
22. Sengenès C, Berlan M, De Glisezinski I, et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14:1345-51. (Pubitemid 30439743)
23. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-8. (Pubitemid 41475811)
24. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-7.
25. Ang DS, Welsh P, Watt P, et al. Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clin Sci (Lond) 2009;117:41-8.
26. Lafontan M, Moro C, Berlan M, et al. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 2008;19:130-7. (Pubitemid 351608304)
27. Dokainish H, Gonzalez R, Hartley WB, et al. Usefulness of B-type natriuretic peptide levels to predict left ventricular filling pressures in patients with body mass index>35, 31 to 35, and
28. Chainani-Wu N, Weidner G, Purnell DM, et al. Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. Am J Cardiol 2010;105:1570-6.
29. Morrow DA, Cannon CP, Jesse RL, et al; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552-74.